Chemical Structure (Eraxis 01)
Eraxis Injection, Powder, Lyophilized, For Solution
Product Images NDC 0049-2242
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Eraxis (NDC 0049-2242). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Roerig, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Logo (Eraxis 02)
This is a text to indicate that the product is distributed by Roerig, which is a division of Pfizer Inc. based in New York, NY 10001.*
Premier Pro Logo (Eraxis 02a)
Principal Display Panel (100 mg Vial Label)
- Store Eraxis® single-dose vial in the refrigerator between 2°C - 8°C (36°F - 46°F). Do not freeze.
- Reconstitute Eraxis® with 30 ml of sterile water for injection. Each mL contains 3.3 mg anidulafungin.
- Further dilute the reconstituted solution with 0.9% Sodium Chloride Injection for IV infusion only.
- Follow recommended dosage instructions provided by your healthcare provider or prescribing information.
- After reconstitution, use the solution within 24 hours. Distributed by Roerig, a division of Pfizer Inc.*
Principal Display Panel (100 mg Vial Carton)
This text provides information about a medication called Eraxis®, which is used for intravenous infusion. It contains anidulafungin and other ingredients. The text includes details on dosage, reconstitution process, storage instructions, and contact information for Premier Healthcare Alliance. It also mentions the importance of following prescribing information for proper use.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
